This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | MicrobiomeTrials
← Back to trials NCT07455851
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-03-26Est. Completion: 2033-09-30
Enrollment target: 150 participantsLocations Prince of Wales Hospital, Randwick, New South Wales, Australia Illawarra Cancer care centre, Wollongong Hospital, Wollongong, New South Wales, Australia Royal Adelaide Hospital, Adelaide, South Australia, Australia St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Alfred Hospital, Melbourne, Victoria, Australia Evangelismos General Hospital, Athens, Attica, Greece Alexandra Hospital, Athens, Attica, Greece Other microbiome trials you might be interested in Relapsed/Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evalua…
Wuhu, China Est. completion Oct 20, 2026
Relapsed/Refractory Multiple Myeloma (RRMM)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk o…
Los Angeles, United States Est. completion Oct 11, 2027